



COMPANY RELEASE

23 May, 2007

AION to present at the 2007 NanoEquity Conference in Frankfurt, Germany

Perth, Australia – AION Diagnostics Inc, a nano-diagnostics company developing medical imaging agents, announced today that it will be presenting at the 3rd Annual NanoEquity Europe Conference. AION will discuss the Company's Molecular Imaging platform as well as its near-term product pipeline.

A Deutsche Börse Group event, NanoEquity Europe combines capital market and equity acquisition with nano and micro-technology company representatives, as well as analysts, investors and key members of the scientific community.

The 2007 NanoEquity Europe Conference will be held June 11-12 at the Hilton Hotel in Frankfurt am Main.

- ENDS -

Released by:

AION Diagnostics

Alexandra Brown

Ph: +61 (8) 6461 9400

alexandra_brown@aiondiagnostics.com

European Public Relations

Dr. Eva Reuter

Ph: +49 (254) 393 0740

e.reuter@e-reuter-ir.com

NOTES TO EDITORS:

AION Diagnostics (AION) is a global biotechnology company dedicated to the commercialization of medical imaging contrast and molecular imaging agents for early stage detection of critical diseases. Founded in 2004, AION secured strategic alliances with universities, research institutions and industry partners internationally.

Exploiting the 10-year history of discoveries of porous silicon made at the former UK Defence Evaluation Agency (now QinetiQ) and backed by USD\$50 million in cumulative previous investment in the technology, AION have developed modified porous silicon (mpSi) which has been proven visible across all major imaging modalities. AION is leveraging the unique visualization capabilities of the mpSi technology platform with its biodegradable and biocompatible properties to produce imaging product divisions in Marking, Contrast and Molecular Imaging Agents. Additionally, one such strategic objective is the development of collaborations incorporating the mpSi platform with other materials to create superior versions of existing products.

Continuing to strive for better solutions to unmet diagnostic needs, AION's products are committed to the timely visualization of pathologies in a manner which may facilitate prevention rather than treatment of disease.

This press release and the information contained therein do not constitute an offer for sale or a solicitation for submission of an offer for purchase or subscription of shares in AION Diagnostics Inc in Germany nor outside Germany, especially in the United States, Canada, Japan or the United Kingdom and Northern Ireland. This press release is provided solely for information purposes.